David Boel
Psychiatric/Mental Health · Nephi, UTNPI 1780091793
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,784 of the $4,600 with a category attached, or 60.5%. 14 manufacturers reported payments, led by AbbVie at 49.5% of the total. Reporting peaked in 2021 at $2,086 and has fallen 50.5% since, to $1,033 in 2025. Among psychiatric/mental health clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $31.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Neurocrine Biosciences, Inc.$545
- Teva Pharmaceuticals USA, Inc.$453
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$363
- Alkermes, Inc.$288
- Axsome Therapeutics, Inc.$165
- plus $509 from 8 others
What the payments were for
- Speaking & faculty fees$1,65036%
- Food & beverage$2,78461%
- Education$1664%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $2,277 |
| Neurocrine Biosciences, Inc. | 22 | $545 |
| Teva Pharmaceuticals USA, Inc. | 19 | $453 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $363 |
| Alkermes, Inc. | 15 | $288 |
| Axsome Therapeutics, Inc. | 6 | $165 |
| Indivior Inc. | 5 | $110 |
| Lundbeck LLC | 5 | $99 |
| Otsuka America Pharmaceutical, Inc. | 7 | $97 |
| Braeburn Inc. | 2 | $88 |
| Sunovion Pharmaceuticals Inc. | 4 | $44 |
| Johnson & Johnson | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$1,650
How this compares
$4,600 in reported general payments places this provider in the 90th percentile of 393 psychiatric/mental health providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 23 | $231,285 |
| VraylarCariprazine Hcl | 88 | $130,686 |
| IngrezzaValbenazine Tosylate | 15 | $121,919 |
| AristadaAripiprazole Lauroxil | 45 | $113,316 |
| TrintellixVortioxetine Hydrobromide | 63 | $33,910 |
| Lamotrigine ErLamotrigine | 13 | $7,216 |
| Clozapine | 106 | $5,967 |
| Risperidone | 208 | $4,844 |
| Aripiprazole | 135 | $4,824 |
| Quetiapine Fumarate | 181 | $4,289 |
| Trazodone Hcl | 212 | $3,728 |
| Prazosin Hcl | 132 | $2,940 |
| Olanzapine | 137 | $2,882 |
| Clonazepam | 153 | $2,691 |
| Lamotrigine | 69 | $2,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza | $30 | $231,28523 claims |
| AbbVieVraylar | $2,277 | $130,68688 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $545 | $121,91915 claims |
| Alkermes, Inc.Aristada | $288 | $113,31645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 393 psychiatric/mental health providers in Utah.
Other psychiatric/mental health in Nephi
- Bret HafenLayton$381K
- Alberto SouzaSaint George$114K
- Anthony BrowningOrem$32K
- Debra HainRiverton$29K
- Kristin BarberSalt Lake City$28K
- Briana TerrySalt Lake City$14K
- Paige MarshallSaint George$13K
- Derick MoodySpringville$8K
- Sumer AndersonSandy$8K
- Colby JamesLayton$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.